Regenxbio (RGNX) Non-Current Assets (2014 - 2025)

Regenxbio's Non-Current Assets history runs 12 years deep, the most recent figure standing at $171.8 million for Q4 2025.

• On a quarterly basis, Non-Current Assets fell 8.64% year-over-year to $171.8 million in Q4 2025; TTM through Dec 2025 was $750.0 million, a 11.79% decrease from a year earlier, with the FY2025 full-year figure at $171.8 million, down 8.64% from the prior year.
• Non-Current Assets retreated to $171.8 million in Q4 2025 per RGNX's latest filing, from $193.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $595.1 million in Q4 2021 and bottomed at $171.8 million in Q4 2025.
• The 5-year median for Non-Current Assets is $285.8 million (2023), against an average of $323.3 million.
• Across the five-year window, Non-Current Assets jumped 236.26% in 2021 and plunged 42.73% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $595.1 million in 2021, then retreated by 29.88% to $417.3 million in 2022, then sank by 42.73% to $239.0 million in 2023, then dropped by 21.34% to $188.0 million in 2024, then decreased by 8.64% to $171.8 million in 2025.
• Per Business Quant, the three latest RGNX Non-Current Assets figures stand at $171.8 million (Q4 2025), $193.2 million (Q3 2025), and $207.3 million (Q2 2025).